Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes

Tomoaki Morioka1*, Masanori Emoto1, Yuko Yamazaki1, Naoya Kawano1, Satoshi Imamura1, Ryutaro Numaguchi1, Hiromi Urata1, Koka Motoyama1, Katsuhito Mori1, Shinya Fukumoto1, Hidenori Koyama2, Tetsuo Shoji3 and Masaaki Inaba1

Abstract

Background: The adipocyte-derived hormone leptin plays a key role in the regulation of appetite and body weight. Recent studies have suggested that leptin is also involved in the pathogenesis of obesity-related atherosclerosis and cardiovascular disease. In this study, we investigated the association of plasma leptin levels with vascular endothelial function in lean and overweight patients with type 2 diabetes.

Methods: One hundred seventy-one type 2 diabetic patients, of which 85 were overweight (body mass index (BMI) ≥ 25 kg/m²), were enrolled in this cross-sectional study. Plasma leptin concentrations were measured by enzyme-linked immunosorbent assay. Flow-mediated dilatation (FMD) of the brachial artery was measured to evaluate vascular endothelial function using ultrasound.

Results: No significant difference in FMD was found between the lean and overweight groups (7.0 ± 3.8% and 6.5 ± 3.6%, respectively; p = 0.354). FMD was negatively correlated with age (r = −0.371, p < 0.001) and serum creatinine levels (r = −0.236, p = 0.030), but positively correlated with BMI (r = 0.330, p = 0.002) and plasma leptin levels (r = 0.290, p = 0.007) in the overweight group. FMD was not associated with any parameters in the lean group. Multiple regression analysis including possible atherosclerotic risk factors revealed that the plasma leptin level (β = 0.427, p = 0.013) was independently associated with FMD in the overweight group (R² = 0.310, p = 0.025), but not the lean group.

Conclusion: Plasma leptin levels are associated with vascular endothelial function in overweight patients with type 2 diabetes.

Keywords: Leptin, Endothelial function, Overweight, Type 2 diabetes

Background

Obesity is a serious health problem worldwide and is associated with established cardiovascular risk factors including hypertension, dyslipidemia, insulin resistance, and diabetes [1]. Adipose tissue exerts endocrine and immune functions by releasing bioactive mediators and adipocytokines such as leptin, adiponectin, resistin, tumor necrosis factor-α, interleukin-6, and monocyte chemotactic protein-1 [2]. Leptin was one of the first adipocytokines identified and has been extensively investigated. Leptin is produced predominantly by adipose tissue and plays a pivotal role in the regulation of appetite and body weight. Plasma leptin levels are markedly elevated in obese individuals, and leptin receptors are widely distributed in peripheral tissue including the cardiovascular system [3]. Therefore, hyperleptinemia may be one potential mechanism linking obesity to atherosclerotic cardiovascular disease. Recent in vitro and in vivo studies have indicated that, in addition to its major roles in energy metabolism, leptin is also involved in the pathophysiology of atherosclerosis [1,2,4]. Moreover, several clinical studies have
shown that the plasma leptin level is an independent predictor of incident coronary artery disease [5,6].

The integrated effect of leptin on vascular endothelial function, a key factor for the initiation and development of atherosclerotic vascular damage [7], remains to be elucidated, since contradictory findings have been reported from experimental and clinical studies. For example, leptin was found to induce endothelium-dependent vascular relaxation by stimulating nitric oxide (NO) in studies using isolated aortic rings of rats [8,9]. Leptin infusion also caused vasodilatation of the brachial artery [10] and coronary artery [11] in non-obese, healthy human subjects. Nonetheless, in pathological conditions such as obesity or metabolic syndrome (MetS), resistance to leptin’s vasodilatory effect has been observed in both animal [12-14] and human studies [15,16]. Obesity and hyperleptinemia caused by diet lead to impaired leptin-induced NO and cyclic guanosine monophosphate production in the aortic wall of rats [12] and in aortic endothelial cells of mice [13]. Knudson et al. [14] performed intracoronary leptin dose–response experiments in anesthetized dogs and found that obese levels of coronary plasma leptin (mean 81 ng/ml) attenuated acetylcholine-induced coronary artery relaxation, whereas normal physiologic levels of leptin (approximately 4 ng/ml) had no effect. Human studies also demonstrated that the serum leptin level is inversely associated with adenosine-stimulated myocardial blood flow in young obese men [15], and with forearm endothelium-dependent vasodilatation (EDV) in the elderly [16]. Nevertheless, controversy persists over whether an independent clinical association between leptin and vascular endothelial function exists, since the associations in the abovementioned studies were no longer present or were attenuated after adjustment for body mass index (BMI) in humans [15,16].

To our knowledge, no study has thus far investigated whether leptin plays a role in vascular endothelial function in patients with type 2 diabetes (T2D), in whom vasodilation mediated by endothelium-derived NO is impaired [17]. Therefore, the aim of the present study was to clarify the cross-sectional association between plasma leptin levels and vascular endothelial function, assessed by flow-mediated dilatation (FMD) of the brachial artery using ultrasound, in patients with T2D.

**Methods**

**Subjects**

We consecutively enrolled 171 subjects with T2D (89 men and 82 women) who were admitted to the Diabetes Center of the Osaka City University Hospital between January 2009 and September 2011. T2D was diagnosed on the basis of the criteria of the American Diabetes Association [18]. Smokers were defined as current or past smokers in our analyses. Subjects were divided into either the lean (BMI < 25 kg/m²) or overweight (BMI 25 ≥ kg/m²) group for analyses. Subjects with type 1 diabetes, other types of diabetes, or renal impairment with a serum creatinine level ≥ 1.1 mg/dL., which is the upper limit of the normal range in our laboratory, were excluded from the present study. All subjects provided written informed consent, and the ethical review board of our institution approved this study protocol.

**Physical and laboratory analyses**

Blood pressure was determined by the conventional cuff method using a mercury sphygmomanometer after subjects rested for at least 15 min. Blood samples were drawn after an overnight fast and biochemical parameters were analyzed by a standard laboratory method as previously described [19]. Immunoreactive insulin was measured for subjects not receiving insulin therapy (n = 108). Plasma leptin levels were measured using enzyme-linked immunosorbent assay kits (R & D Systems, Minneapolis, MN). The minimum detectable level of leptin was 0.16 ng/mL, and the intra- and inter-assay coefficients of variation were 3.2% and 3.5%, respectively [20].

**Measurement of FMD**

We measured FMD of the brachial artery according to the International Brachial Artery Reactivity Task Force guidelines [21] and the Japanese guidelines of the Vascular Failure Workshop Group [22] using a novel ultrasound system equipped with an edge-tracking system for 2D imaging and a pulsed Doppler flow velocimeter for automatic measurement (UNEXEF; Unex Co. Ltd., Nagoya, Japan), as we [23] and others [24,25] previously described. In brief, the diameter of the brachial artery at rest was measured in the cubital region. Subsequently, the cuff was inflated to 50 mmHg above systolic blood pressure (SBP) for 5 min and then deflated. The diameter of the artery was monitored continuously at the same point, and the maximum dilatation from 45–60 s after deflation was recorded. Following FMD measurement, endothelium-independent nitroglycerin-mediated dilatation (NMD) was also measured. After a 15-min rest for vessel recovery, sublingual nitroglycerin (75 μg) was administered, and the maximum dilatation of the brachial artery at the same point was measured during at least 1 min after the initiation of maximum dilatation. FMD and NMD were calculated as follows: FMD or NMD (%) = (maximum diameter – diameter at rest) × 100/diameter at rest.

**Statistical analysis**

Statistical analyses were performed using the JMP® 9 software (SAS Institute Inc., Cary, NC). All results were expressed as mean ± standard deviation (SD) or median (interquartile range) as appropriate. Student’s t-test, Wilcoxon rank-sum test, or χ²-test was performed.
where appropriate for comparisons between the lean and overweight groups. Simple linear regression analyses and multiple regression analyses were performed to evaluate the relationships between FMD and various clinical parameters including plasma leptin level. Skewed parameters such as immunoreactive insulin, triglycerides, and plasma leptin levels were logarithmically transformed before regression analyses. In multiple regression analyses, FMD was the dependent variable and plasma leptin level as well as age; sex; BMI; waist circumference; SBP; creatinine level; HbA1c; triglyceride level; high-density lipoprotein-cholesterol (HDL-C) level; low-density lipoprotein-cholesterol (LDL-C) level; smoking status; and treatment with insulin, statins, or angiotensin-II receptor blockers or angiotensin-converting enzyme inhibitors (ARB/ACEI) were independent variables. A p-value < 0.05 was considered significant.

Results

Clinical characteristics of the subjects

The clinical characteristics of the lean and overweight groups as well as the total population are shown in Table 1. The mean ± SD for the age of all subjects was 63 ± 10 years (range, 36–86 years). Twenty subjects were treated with dietary therapy alone, 88 with oral hypoglycemic agents, 39 with insulin, and 24 with a combination of insulin and oral hypoglycemic agents. Seventy-one subjects were treated with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) and 72, with ARB/ACEI. Overweight subjects were significantly younger than the lean subjects. As expected, overweight subjects had higher diastolic blood pressure (DBP), plasma insulin, insulin resistance index by homeostasis model assessment (HOMA-R), serum triglycerides, uric acid levels and lower high-density lipoprotein cholesterol (HDL-C) levels than the lean subjects. There were no significant differences among the lean and overweight groups for frequency of smoking, insulin use, ARB/ACEI, or statin treatment. The median plasma leptin level for all subjects was 4.1 (2.0–8.0) ng/mL. Plasma leptin levels in the overweight group were also significantly higher than that in the lean group (5.9 (3.2–9.8) vs. 2.5 (1.2–4.8) ng/mL, p < 0.001). Mean FMD for the total population was 6.8 ± 3.7% (range, 0.7–18.5), and no significant differences between overweight and lean subjects was found (6.5 ± 3.6% vs. 7.0 ± 3.8%, p = 0.354). Mean NMD was also not statistically different between the two groups (15.5 ± 7.3% vs. 14.6 ± 6.6%, p = 0.424).

Association between plasma leptin levels and FMD

First, we examined the association between FMD and plasma leptin levels or clinical risk factors for atherosclerosis by simple linear regression analyses for the total population and then for lean and overweight subjects separately (Table 2). In all subjects, age and creatinine level were significantly and negatively correlated with FMD. In the lean group, none of the parameters were significantly correlated with FMD. Age, waist-to-hip ratio and creatinine level were negatively correlated with FMD, and BMI was positively correlated with FMD in the overweight group. Plasma leptin levels exhibited a significant, positive correlation with FMD in the overweight group, but not the lean group or the total population (Table 2 and Figure 1). Consistent with previous reports [23,26], NMD was negatively associated with age, waist circumference, waist-to-hip ratio, SBP, and creatinine level in all, lean and/or overweight subjects. However, plasma leptin levels were not associated with NMD in either the lean or overweight group, which is in contrast to the relationship we found between plasma leptin levels and FMD. In subjects not receiving insulin therapy (n = 108), plasma leptin levels were also significantly correlated to FMD (r = 0.337, p = 0.009), but not to NMD (r = 0.224, p = 0.088), whereas insulin resistance assessed by HOMA-R was not correlated to FMD (r = −0.023, p = 0.873) or NMD (r = −0.124, p = 0.382), in the overweight group (n = 59).

In keeping with the positive correlation between plasma leptin and FMD, subjects with plasma leptin above the median (4.1 ng/mL) exhibited greater FMD than those with plasma leptin below the median (7.3 ± 4.0 vs. 6.2 ± 3.2%, p = 0.042) (Figure 2). Mean NMD was not different between subjects with plasma leptin above and below the median (14.9 ± 7.5 and 15.2 ± 6.5%, respectively, p = 0.799).

Since FMD could be affected by various clinical factors and medication use for diabetes, hypertension, or dyslipidemia [27,28], multiple regression analyses were performed in order to identify the impact of plasma leptin on FMD while controlling for important confounders in all, lean and overweight subjects, as described in the Statistical analysis section (Table 3). Among all independent variables, only plasma leptin levels (β = 0.427, p = 0.013), but not BMI (β = 0.107, p = 0.648) or waist circumference (β = −0.186, p = 0.362), significantly contributed to FMD in the overweight group. However, in the lean group, no parameters were significantly associated with FMD (R^2 = 0.111, p = 0.885).

Discussion

The present study demonstrated that plasma leptin levels are positively related to vascular endothelial function in overweight T2D patients, but not in lean patients. Of importance, plasma leptin level was a significant contributing factor to FMD, independent of BMI, blood pressure and other traditional cardiovascular risk factors, in overweight T2D patients. Our findings suggest that leptin exerts its positive and vasodilator effect on endothelial function in
overweight diabetic patients with an elevated risk for cardiovascular diseases. A number of clinical studies have investigated the association between plasma leptin levels and vascular endothelial function [16,29-31]. Plasma leptin levels were reported to be negatively associated with EDV measured by forearm plethysmography in the elderly subjects [16], and with FMD of the brachial artery in patients with nonalcoholic fatty disease [29] and polycystic ovarian syndrome [30]. However, the association of plasma leptin with vascular endothelial function was not independent of the other variables including BMI in these studies. Plasma leptin-to-adiponectin ratio was also shown to be negatively associated with FMD in healthy elderly subjects [31]. In the other studies, plasma leptin levels were not associated with FMD of the brachial artery [32-37]. FMD was evaluated after weight reduction by low-calorie diet for obese subjects in several studies [38-41]. Increased FMD after weight loss was negatively [38], positively [39], or not [40,41] associated with change in plasma leptin levels. These previous cross-sectional and interventional studies demonstrate inconsistent results on the relationship between leptin and endothelial function, possibly because the study subjects or the method used to estimate endothelial function differs. The findings of our study contrast with those of these previous studies in that the association of leptin levels with FMD was independent of confounding cardiovascular risk factors such as age, BMI, SBP, and lipids in overweight T2D patients. In addition, moderately elevated plasma leptin levels unexpectedly exhibited a positive relation with FMD in overweight patients with T2D in this study. These patients are also generally at a high risk for atherosclerosis and cardiovascular disease.

Functional leptin receptors are expressed in vascular endothelium [9]. Several experimental studies showed that acutely administered leptin induces endothelium-dependent vasorelaxation by stimulating the release of endothelial NO or the endothelium-derived hyperpolarizing factor (EDHF).
in rats [8,9,42], or by neuronal NO synthase in mice [43]. Endothelium-independent vasodilation by leptin was also identified in the saphenous vein and internal mammary artery ex vivo in humans with coronary artery disease [44]. A direct vasodilator effect of acute leptin infusion has also been investigated in several human studies. Nakagawa et al. [10] reported forearm vasodilatation by intra-arterial infusion of leptin, and coronary artery vasodilation by intra-coronary leptin infusion in a separate study [11]. The leptin-induced vasodilatation was independent of NO and possible involvement of other vasoactive agents such as the EDHF or prostacyclin was suggested in those human studies. Brook et al. [45] demonstrated that brachial FMD increased 2 hours following subcutaneous injection of recombinant human leptin without altering blood pressure in non-obese adults. These studies imply that the selective leptin resistance seen in obesity may not be limited to appetite and body weight control, but may involve the hemodynamic actions of leptin, thus leading to the pro-atherogenic effects of leptin on vasculature [50]. However, to date, no previous study has demonstrated an independent association of leptin with brachial artery FMD assessed by ultrasound, in human subjects with obesity and/or MetS. High leptin concentrations were also reported to be associated with impaired EDV measured by forearm plethysmography [16] and inversely with adenosine-stimulated coronary blood flow [15] in human subjects, but those associations were not independent of BMI and/or insulin levels. These experimental and clinical studies indicate that the NO-dependent vasodilatory effects of leptin become impaired, and by this mechanism, leptin may contribute to endothelial dysfunction and the progression of atherosclerosis in patients with obesity and/or MetS. To our knowledge, this is the first study to explore the association of leptin with vascular endothelial function

| Table 2 Correlations between FMD, NMD, and clinical variables in subjects with type 2 diabetes |
|-----------------------------------------|----------|----------|----------|
|                                       | All subjects | Lean | Overweight | All subjects | Lean | Overweight |
| r, p correlation coefficient by simple regression analysis. Abbreviations are the same as Table 1. |
| Age                                     | −0.175 | 0.022 | −0.007 | 0.948 | −0.371 | <0.001 | −0.425 | <0.001 | −0.382 | <0.001 | −0.545 | <0.001 |
| BMI                                      | 0.101 | 0.191 | 0.034 | 0.756 | 0.330 | 0.002 | −0.044 | 0.572 | −0.192 | 0.077 | 0.111 | 0.313 |
| Waist                                   | 0.014 | 0.852 | 0.005 | 0.967 | 0.155 | 0.159 | −0.169 | 0.028 | −0.287 | 0.008 | −0.051 | 0.648 |
| Waist-to-hip ratio                      | −0.134 | 0.083 | 0.067 | 0.545 | −0.285 | 0.009 | −0.220 | 0.004 | −0.200 | 0.067 | −0.225 | 0.040 |
| SBP                                     | −0.123 | 0.110 | −0.054 | 0.622 | −0.193 | 0.076 | −0.315 | <0.001 | −0.405 | <0.001 | −0.213 | 0.051 |
| DBP                                     | 0.032 | 0.676 | 0.172 | 0.113 | −0.059 | 0.593 | −0.005 | 0.946 | −0.053 | 0.627 | 0.065 | 0.555 |
| Cre                                     | −0.168 | 0.028 | −0.090 | 0.409 | −0.236 | 0.030 | −0.161 | 0.036 | −0.084 | 0.441 | −0.235 | 0.031 |
| Glucose                                 | −0.050 | 0.519 | −0.117 | 0.284 | 0.015 | 0.893 | −0.069 | 0.370 | −0.033 | 0.765 | −0.118 | 0.284 |
| HbA1c                                   | −0.147 | 0.055 | −0.174 | 0.108 | −0.125 | 0.253 | 0.012 | 0.875 | 0.029 | 0.788 | −0.021 | 0.846 |
| Log [IRI]                                | −0.049 | 0.622 | −0.009 | 0.954 | 0.035 | 0.799 | −0.069 | 0.487 | −0.068 | 0.642 | −0.019 | 0.892 |
| Log [HOMA-R]                             | −0.047 | 0.639 | 0.007 | 0.961 | 0.013 | 0.925 | −0.125 | 0.206 | −0.140 | 0.338 | −0.071 | 0.608 |
| Log [TG]                                 | 0.025 | 0.746 | 0.024 | 0.829 | 0.056 | 0.614 | 0.024 | 0.756 | 0.082 | 0.455 | −0.037 | 0.739 |
| HDL-C                                   | 0.025 | 0.748 | −0.016 | 0.881 | 0.045 | 0.682 | −0.098 | 0.203 | −0.116 | 0.286 | −0.115 | 0.295 |
| LDL-C                                   | −0.004 | 0.962 | −0.108 | 0.324 | 0.105 | 0.339 | 0.135 | 0.079 | 0.176 | 0.106 | 0.085 | 0.442 |
| Uric acid                                | 0.069 | 0.369 | 0.024 | 0.827 | 0.147 | 0.179 | −0.016 | 0.838 | 0.018 | 0.873 | −0.027 | 0.809 |
| Log [Leptin]                             | 0.136 | 0.077 | 0.107 | 0.329 | 0.290 | 0.007 | −0.0003 | 0.997 | −0.0001 | 0.999 | 0.070 | 0.522 |

r, p correlation coefficient by simple regression analysis. Abbreviations are the same as Table 1.
in patients with T2D. We found an independent and positive association between plasma leptin levels and FMD in overweight (BMI ≥ 25 kg/m²), but not lean subjects, even after adjustment for other confounders including age, BMI, SBP, HbA1c, and lipid levels. The positive association between plasma leptin levels and FMD in patients with diabetes is contrary to previous studies that show an association between hyperleptinemia and impaired endothelial function in human subjects with obesity or MetS. There are several possible explanations for this discrepancy. First, the degree of obesity in our Japanese patients was much less than that of the studies performed in European countries, which demonstrated a resistance to leptin-induced vasoreactivity in human subjects with obesity or MetS [15,49]. BMI and plasma leptin levels were 33.6 kg/m² and 10.3 ng/mL, respectively, in obese subjects from the study by Sundell and colleagues [15], and 38 kg/m² and 21.2 ng/mL, respectively, in subjects with MetS in the study by Schinzari and colleagues [49]. These BMI and leptin levels are much higher than those of our overweight subjects (BMI, 28.4 kg/m²; leptin levels, 6.0 ng/mL). Moreover, the plasma leptin levels of our overweight subjects were similar to those of the healthy [15] and control subjects [49], at 4.3 ng/mL and 8.7 ng/mL, respectively, in two studies from Europe. Therefore, the vasodilator effect of leptin could have still been activated in our overweight subjects because their leptin levels were not very hyperleptinemic. In addition, plasma leptin did not exhibit a significant association with FMD in our lean subjects. This could be due to their low leptin levels (2.5 ng/mL), at which leptin has not been found to exert significant vasodilation in Japanese subjects [10]. Second, forearm plethysmography reflects endothelial function of the resistance artery mediated mainly by the EDHF, whereas FMD reflects the conduit artery by NO [9]. An animal study showed that even if the endothelial NO synthase-derived NO production is impaired or absent, leptin can induce neuronal NO synthase in the endothelium to maintain endothelium dependent-vasorelaxation in a mouse model of obesity with hyperleptinemia or angiotensin-II-induced vascular dysfunction [43]. Therefore, in this study, NO-mediated vasodilation assessed with FMD of the brachial artery was observed in overweight diabetic subjects with mildly elevated plasma leptin levels. Third, overweight subjects in this study were significantly younger than the lean subjects. Endothelial dysfunction assessed by FMD is recognized as an early marker of vascular damage, contributing to the initiation and progression of atherosclerosis [7]. Although intima-media thickness of the carotid artery was observed in overweight diabetic subjects with mildly elevated plasma leptin levels. Our results further demonstrated that plasma leptin levels were also independently and positively associated with NMD in both lean and overweight subjects and
those associations were found only after adjusting for other confounders including age, obesity, BP, and lipids. The vasodilator response to exogenous NO reflects vascular smooth muscle function and is reported to be impaired independently of endothelial dysfunction in subjects at risk for atherosclerosis [26]. Apart from the endothelium, leptin was also shown to directly target vascular smooth muscle cells via NO-dependent [51] and NO/endothelium independent [44] manner. Thus, the correlation between leptin and NMD in both lean and overweight subjects may reflect the smooth muscle-dependent vasodilator effect of leptin, which can be observed even in lean T2D patients with low plasma leptin levels.

There were a few limitations of our study. First, this was a cross-sectional study; therefore, a causal relationship between plasma leptin and FMD cannot be clarified. Second, the patients with T2D in this study were receiving various anti-atherogenic drug interventions such as antihypertensive agents, statins and insulin therapy that can exert considerable effects on FMD of the brachial artery and related atherosclerotic risk factors. To minimize the effect of such treatments, we adjusted for patient treatment status in our multivariate analyses. Third, our overweight subjects were significantly younger than the lean subjects. A positive relationship between BMI and FMD was also found in the univariate analysis. Since all potential

---

**Table 3 Multivariate analyses of the determinants for FMD and NMD in subjects with type 2 diabetes**

|                    | FMD All subjects |          | Lean |          | Overweight |          | Lean |          | Overweight |          | Lean |          | Overweight |          | Lean |          | Overweight |          |
|--------------------|------------------|----------|------|----------|------------|----------|------|----------|------------|----------|------|----------|------------|----------|------|----------|------------|----------|
| Age (years)        | −0.178           | 0.081    | −0.058| 0.692    | −0.246     | 0.096    | −0.453| <0.001   | −0.149     | 0.227    | −0.724| <0.001   | −0.050     | 0.647    | −0.250| 0.196    | −0.346     | 0.089    |
| Sex (male = 1)     | 0.007            | 0.783    | −0.014| 0.917    | 0.167      | 0.379    | 0.116 | 0.310    | 0.214      | 0.217    | 0.028 | 0.863    | 0.107      | 0.339    | 0.200 | 0.217    | 0.385      | 0.005    |
| BMI (kg/m²)        | 0.035            | 0.860    | −0.037| 0.871    | 0.107      | 0.648    | −0.150| 0.374    | −0.250     | 0.196    | −0.346| 0.089    | 0.105      | 0.339    | 0.200 | 0.217    | 0.385      | 0.005    |
| Waist (cm)         | −0.150           | 0.403    | 0.048 | 0.807    | −0.186     | 0.362    | −0.366| 0.018    | −0.237     | 0.157    | −0.131| 0.457    | −0.167     | 0.377    | 0.001 | 0.378    | 0.002      | 0.203    |
| SBP (mmHg)         | −0.094           | 0.271    | −0.064| 0.643    | −0.220     | 0.069    | −0.241| 0.001    | −0.378     | 0.002    | −0.203| 0.053    | −0.130     | 0.307    | 0.003 | 0.035    | −0.003      | 0.950    |
| Cre (mg/dL)        | −0.046           | 0.644    | 0.054 | 0.732    | −0.031     | 0.824    | −0.076| 0.375    | 0.010      | 0.941    | −0.073| 0.548    | −0.083     | 0.514    | 0.025 | 0.714    | −0.031      | 0.950    |
| HbA1c (%)          | −0.186           | 0.034    | −0.155| 0.314    | −0.138     | 0.207    | −0.009| 0.907    | 0.011      | 0.931    | −0.006| 0.953    | −0.098     | 0.231    | −0.057| 0.691    | −0.096      | 0.350    |
| Log [TG (mg/dL)]   | 0.000            | 0.999    | −0.035| 0.836    | 0.110      | 0.355    | −0.098| 0.231    | −0.057     | 0.691    | −0.096| 0.350    | 0.009      | 0.591    | −0.057| 0.691    | −0.096      | 0.350    |
| HDL-C (mg/dL)      | 0.097            | 0.325    | 0.079 | 0.625    | 0.046      | 0.703    | −0.125| 0.134    | −0.078     | 0.564    | −0.233| 0.027    | −0.050     | 0.494    | 0.045 | 0.694    | −0.189      | 0.087    |
| LDL-C (mg/dL)      | −0.051           | 0.554    | −0.107| 0.432    | 0.014      | 0.912    | −0.050| 0.494    | 0.045      | 0.694    | −0.189| 0.087    | 0.026      | 0.732    | 0.064 | 0.580    | −0.039      | 0.730    |
| Smoking (yes = 1)  | −0.080           | 0.378    | −0.053| 0.702    | −0.049     | 0.712    | 0.026 | 0.732    | 0.064      | 0.580    | −0.039| 0.730    | 0.026      | 0.732    | 0.064 | 0.580    | −0.039      | 0.730    |
| Insulin (yes = 1)  | −0.050           | 0.572    | −0.175| 0.236    | 0.056      | 0.646    | −0.073| 0.338    | −0.155     | 0.210    | −0.066| 0.530    | −0.035     | 0.747    | 0.008 | 0.942    | −0.032      | 0.727    |
| Statins (yes = 1)  | 0.008            | 0.915    | 0.037 | 0.768    | −0.035     | 0.747    | −0.030| 0.652    | 0.008      | 0.942    | −0.032| 0.727    | 0.034      | 0.004    | 0.462 | 0.011    | 0.318      | 0.031    |
| ARB/ACEI (yes = 1) | −0.104           | 0.209    | −0.069| 0.576    | −0.171     | 0.151    | −0.040| 0.572    | −0.020     | 0.846    | −0.019| 0.851    | −0.040     | 0.572    | 0.064 | 0.580    | −0.039      | 0.730    |
| Log [Leptin (ng/mL)]| 0.158           | 0.246    | 0.038 | 0.859    | 0.427      | 0.013    | 0.341 | 0.004    | 0.462      | 0.011    | 0.318 | 0.031    | 0.341      | 0.004    | 0.462 | 0.011    | 0.318      | 0.031    |
| R²                 | 0.132            | 0.094    | 0.111 | 0.885    | 0.310      | 0.025    | 0.372 | <0.001   | 0.376      | 0.002    | 0.485 | <0.001   | 0.376      | 0.002    | 0.485 | <0.001   | 0.485      | <0.001   |

β, standard correlation coefficient by multiple regression analysis; R², multiple coefficients of determination. Abbreviations are the same as Table 1.
confounding risk factors could not be adjusted for with the
consecutive inclusion of our subjects, factors including
age and BMI were adjusted for and the independent
association of leptin was confirmed in the multivariate
analyses. Fourth, no healthy controls were used to
compare our findings, and we could not confirm that FMD
was impaired in our study population of T2D patients.
Last, this study included a very low number of morbidly
obese patients with a BMI ≥ 30 kg/m² (n = 15, 88.8%); thus,
our results are only applicable to normal or overweight
T2D patients. Leptin could contribute differently to FMD
in morbidly obese patients with more severe leptin
resistance and hyperleptinemia than overweight subjects
[15,49,52].

Further studies with a larger population that includes
T2D patients with a wide range of BMI are required to
validate these findings. Furthermore, prospective and
interventional studies assessing changes in both plasma
leptin levels and FMD are warranted to clarify whether plasma leptin levels are predictive of vascular endothelial
function in patients with obesity and T2D.

Conclusions

Our data demonstrate that the plasma leptin level is an
independent determinant of better FMD of the brachial
artery in overweight, but not lean, patients with T2D. The
present study provides clinical evidence that leptin is asso-
ciated with vascular endothelial function in T2D patients
with moderate obesity.

Abbreviations

BMI: Body mass index; FMD: Flow-mediated dilation; NO: Nitric oxide;
MetS: Metabolic syndrome; EDV: Endothelial-dependent vasodilation;
T2D: Type 2 diabetes; SBP: Systolic blood pressure; NMD: Endothelium-
independent nitroglycerin-mediated dilation; SD: Standard deviation; LDL-
C: Low-density lipoprotein cholesterol; ARB: Angiotensin-II receptor blockers;
ACEI: Angiotensin-converting enzyme inhibitors; HDL-C: High-density lipoprotein cholesterol; EDHF: Endothelium-derived hyperpolarizing factor.

Competing interests

The authors declare that they have no competing interest.

Authors’ contributions

TM and ME conceived of the study, participated in its design and
coordination, and helped to draft the manuscript. TM carried out the
immunoassays, and performed the statistical analysis. YY, NK, SI, RN, and HU
recruited patients and carried out the vascular ultrasound. KMot, KMor, SF,
TM and ME conceived of the study, participated in its design and
coordination, and helped to draft the manuscript. TM carried out the
regression analysis. KMot, KMor, SF, TM, and ME conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript. TM and ME conceived of the study, participated in its design and
coordination, and helped to draft the manuscript. TM carried out the
vascular ultrasound. KMot, KMor, SF, TM, and ME conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript. TM and ME conceived of the study, participated in its design and
coordination, and helped to draft the manuscript. TM carried out the
vascular ultrasound. KMot, KMor, SF, TM, and ME conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript.

Acknowledgements

This study was supported by a Grant-in-Aid for Scientific Research (No. 20591068)
from the Japan Society for the Promotion of Science (to ME and KM). No other
potential conflicts of interest relevant to this article were reported.

Author details

1 Departments of Metabolism, Endocrinology and Molecular Medicine, 1-4-3,
Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 2 Department of Internal
Medicine, Division of Endocrinology and Metabolism, Hyogo College of
Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
3 Department of Geriatrics and Vascular Medicine, Osaka City University Graduate
School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.

Received: 15 October 2013 Accepted: 8 January 2014
Published: 10 January 2014

References

1. Beltowski J: Leptin and atherosclerosis. Atherosclerosis 2006, 189(1):47–60.
2. Guzik TJ, Mangalat D, Keifu B: Adipocytokines - novel link between
inflammation and vascular function? J Physiol Pharmacol 2006, 57(4):505–528.
3. Aihara RS, Frier BS, Leptin. Annu Rev Physiol 2000, 62:413–437.
4. Dubey B, Hesong Z: Role of leptin in atherogenesis. Exp Clin Cardiol 2006, 11(4):269–275.
5. Soderberg S, Ahrens B, Jansson JH, Johnson O, Hallmans G, Asplund K,
Olsson T: Leptin is associated with increased risk of myocardial
infarction. J Intern Med 1999, 246(4):406–418.
6. Wallace AM, McManon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N:
Plasma leptin and the risk of cardiovascular disease in the west of Scotland
coronary prevention study (WOSCOPS). Circulation 2001, 104(25):3052–3056.
7. Tomiyama H, Yamashina A: Non-invasive vascular function tests: their
pathophysiological background and clinical application. Circ J 2010, 74(1):24–33.
8. Kımura K, Tsuda K, Baba A, Kawabe T, Bok-oka S, Itaba M, Moriwake C, Hano T,
Nicho I: Involvement of nitric oxide in endothelium-dependent arterial
relaxation by leptin. Biochem Biophys Res Commun 2000, 273(2):745–749.
9. Lembo G, Vecchione C, Fiatta L, Marino G, Trimarco V, D’Amato G, Trimarco B:
Leptin induces direct vasodilatation through distinct endothelial
mechanisms. Diabetes 2000, 49(2):293–297.
10. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K:
Leptin causes vasodilatation in humans. Hypertens Res 2002, 25(2):161–165.
11. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K:
Leptin causes nitric-oxide independent coronary artery vasodilatation in
humans. Hypertens Res 2003, 26(2):147–152.
12. Beltowski J, Wojcicka G, Jamroz-Wisniewska A, Marciniak A:
Resistance to acute NO-mimetic and EDHF-mimetic effects of leptin in the metabolic
syndrome. Life Sci 2009, 85(15–16):557–567.
13. Korda M, Kubant R, Patton S, Malinski T: Leptin-induced endothelial
dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008, 295(4)(H1514):1521.
14. Knudson JD, Dincer UD, Zhang C, Swafford AN Jr, Koshida R, Picciti A,
Focardi M, Dick GM, Tune JD. Leptin receptors are expressed in coronary
arteries, and hyperleptinemia causes significant coronary endothelial
dysfunction. Am J Physiol Heart Circ Physiol 2005, 289(1):H448–56.
15. Sundell J, Huupponen R, Raitakari OT, Nuutinen P, Knuuti J: High serum leptin is
associated with attenuated coronary vasoreactivity. Obes Res 2003, 11(6):776–782.
16. Gonzalez M, Lind L, Soderberg S, Leptin and endothelial function in the
elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS)
study. Atherosclerosis 2013, 228(2):485–490.
17. Cosentino F, Luscher TF: Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998, 32(Suppl 3):S54–S61.
18. American Diabetes Association: Standards of medical care in diabetes–2013.
Diabetes Care 2013, 36(Suppl 1):S1–S66.
19. Yamazaki Y, Emoto M, Morikoa T, Kawano N, Lee E, Urata H, Tsuchikura S,
Motoyama K, Mori K, Fukumoto S, et al: Clinical impact of the leptin to
soluble leptin receptor ratio on subclinical carotid atherosclerosis in
patients with type 2 diabetes. J Atheroscler Thromb 2013, 20(2):186–194.
20. Golledge J, Clancy P, Jamrozik K, Norman PE: Endothelial dysfunction and
abdominal aortic aneurysm: health in men study. Circulation 2007, 116(20):2275–2279.
21. Cornetti MC, Anderson TJ, Benjamin EJ, Celemajer D, Charbonneau F,
Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herington D, et al:
Guidelines for the ultrasound assessment of endothelial-dependent
flow-mediated vasodilation of the brachial artery: a report of the
International brachial artery reactivity task force. J Am Coll Cardiol 2002,
39(2):257–265.
22. Itoue T, Matsuoka H, Higashi Y, Ueda S, Sata M, Shiramda KE, Ishibashi Y,
Noda K: Flow-mediated vasodilation as a diagnostic modality for vascular
failure. Hypertens Res 2008, 31(12):12105–2113.
23. Kawano N, Emoto M, Mori K, Yamazaki Y, Urata H, Tsuchikura S, Motoyama K,
Morikoa T, Fukumoto S, Shoji T, et al: Association of endothelial and vascular
smooth muscle dysfunction with cardiovascular risk factors, vascular
complications, and subclinical carotid atherosclerosis in type 2 diabetic
patients. J Atheroscler Thromb 2012, 19(6):276–284.
24. Maruhashi T, Soga J, Fujimura N, Idei N, MIkami S, Iwamoto Y, Kajikawa M, Matsutomo T, Hitada T, Kiraha Y, et al. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. *Atherosclerosis Thromb: Vasc Biol* 2013, 33(6):1401–1408.

25. Tomiyama H, Hiigash Y, Takase B, Node K, Sata M, Inoue T, Isumi T, Ueda S, Shimada K, Yamashina A. Relationships among hyperuricemia, metabolic syndrome, and endothelial function. *Ann Hematol* 2011, 90(7):770–774.

26. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, CemlerJar D. Smooth muscle dysfunction occurs independently of impaired endothelial-dependent dilation in adults at risk of atherosclerosis. *J Am Coll Cardiol* 1998, 32(1):127–137.

27. Kuh KK, Han SH, Oh PC, Shin EK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. *Atherosclerosis* 2010, 209(2):307–313.

28. Tomiyama H, Matsumoto C, Yamada J, Teramoto T, Abe K, Ohta H, Kiso Y, Kawauchi T, Yamashina A. The relationships of cardiovascular disease risk factors to flow-mediated dilatation in Japanese subjects free of cardiovascular disease. *Hypertens Res* 2008, 31(11):2019–2025.

29. Vlachopoulos C, Manesis E, Baxi K, Papatheodoridis G, Koskinas J, Tiniakos D, Asmarouidis K, Archimandritis A, Stefanis C. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. *Ann Hematol* 2010, 93(S1):1183–1189.

30. Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, de Aloysio D. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. *Nutr Diabetes* 2013, 3:10.

31. Narita K, Murata T, Hamada T, Kosaka H, Sudo S, Mizukami K, Yoshida H, Wada Y. Associations between trait anxiety, insulin resistance, and endothelial function and its relationship to leptin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. *Fertil Steril* 2009, 91(6):2537–2544.

32. Golledge J, Leicht AS, Crosswright RG, Glanville S, Clancy P, Sangska KS, Spinks WL, Quigley F. Determinants of endothelial function in a cohort of patients with peripheral artery disease. *Cardiology* 2008, 111(1):51–56.

33. Gupta AK, Johnson WD, Johannsen D, Ravussin E. Increased arterial stiffness and increased nitric oxide bioavailability in young Black African men. *Hypertension* 2007, 49(4):873–877.

34. Offaz H, Goby N, Mantar F, Genschall H, Mercangolu F, Sencer E, Molvallar S, Orhan Y. Determination of endothelial function and early atherosclerotic changes in healthy obese women. *Diabetes Nutr Metab* 2003, 16(7):176–181.

35. Saarikoski LA, Huupponen RK, Villari JS, Marnimie J, Juonala M, Kahonen M, Raitakari OT. Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults—the cardiovascular risk in young Finns study. *Ann Med* 2010, 42(8):603–611.

36. Singh J, Farrow J, Cole TJ, O’Rahilly S, Frewitt M, Kattenhorn M, Lucas A, Deanfield J. Inhibition of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? *Circulation* 2002, 106(15):1919–1924.

37. Van der Loo J, Bhatia S, Kellum MP, Phillips SA. Improvements in vascular health by a low-fat diet, but not a high-fat diet, are mediated by changes in adipocyte biology. *Nutr J* 2011, 10(8).

38. Mohler ER 3rd, Sibley AA, Stein R, Davila-Roman V, Wyatt H, Badelatto K, Rader D, Klein S, Foster GD. Endothelial function and weight loss: comparison of low-carbohydrate and low-fat diets. *Obesity (Silver Spring)* 2013, 21(3):504–509.

39. Kellum MP, Kroeger CM, Norveikute E, Goslavski M, Phillips SA, Van der Loo J. Benefit of a low-fat over high-fat diet on vascular health during alternate day fasting. *Nutr Diabetes* 2013, 3:e71.

40. Mavri A, Poredes P, Suran D, Gaborit B, Juhun-Valgate I. Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting. *Heart Vessels* 2013, 28(1):51–58.

41. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. *Diabetes* 1999, 48(4):903–908.

42. Benkloff S, Loot AE, Pierson J, Sturza A, Kohlstedt K, Fleming I, Shimokawa H, Grisko, Brandes RP, Schrader K. Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. *Atherosclerosis* Thromb Vasc Biol 2012, 32(7):1605–1612.

43. Momin AU, Melkian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, et al. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. *Eur Heart J* 2006, 27(19):2294–2299.

44. Brook RD, Bard RL, Bodary PF, Eitzman DT, Rajagopalan S, Sun Y, Depaoli AM. Blood pressure and vascular effects of leptin in humans. *Metab Syndr Relat Disord* 2007, 5(5):270–274.

45. Jung CH, Kim BY, Kim CH, Kang SK, Jung SH, Mok JO. Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients. *Cardiovasc Diabetol* 2012, 11:24.

46. Beltovskij J. Leptin and the regulation of endothelial function in physiological and pathological conditions. *Clin Exp Pharmacol Physiol* 2012, 39(2):168–178.

47. Chiu FH, Chuang CH, Li WC, Weng YM, Fann WC, Lo HY, Sun C, Wang SH. The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults. *Cardiovasc Diabetol* 2012, 11:40.

48. Schinazi F, Tesauro M, Rovella V, Di Daniela N, Mores N, Veneziani A, Cardillo C. Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity-related metabolic syndrome. *J Clin Endocrinol Metab* 2013, 98(3):1235–1241.

49. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. *J Am Coll Cardiol* 2008, 52(15):1210–1211.

50. Rodriguez A, Fortuno A, Gomez-Ambrosio I, Zaba G, Diez J, Fruhbeck G. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. *Endocrinology* 2007, 148(1):324–331.

51. Quercioli A, Pataky Z, Montecucco F, Carballo S, Thomas A, Staub C, Di Marzo V, Vincenti G, Ambrosio G, Ratib O, et al. Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. *JACC Imaging* 2012, 5(8):805–815.